| Autor: |
Mohammed OJ; Children's Brain Tumour Research Centre, School of Medicine, University of Nottingham, Nottingham NG7 2RD, UK., Cebrero ME; Children's Brain Tumour Research Centre, School of Medicine, University of Nottingham, Nottingham NG7 2RD, UK., Ahmad O; Children's Brain Tumour Research Centre, School of Medicine, University of Nottingham, Nottingham NG7 2RD, UK., Peet A; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2SY, UK.; Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham B15 2TG, UK., Grundy RG; Children's Brain Tumour Research Centre, School of Medicine, University of Nottingham, Nottingham NG7 2RD, UK., Lourdusamy A; Children's Brain Tumour Research Centre, School of Medicine, University of Nottingham, Nottingham NG7 2RD, UK. |
| Abstrakt: |
Medulloblastoma (MB) is a childhood malignant brain tumour but also occurs in teenagers and young adults (TYA). Considering that MB is heterogeneous, this study aimed to define the molecular landscape of MBs in TYAs. We collated more than 2000 MB samples that included 287 TYA patients (13-24 years). We performed computational analyses consisting of genome-wide methylation and transcriptomic profiles and developed a prognostics model for the TYAs with MB. We identified that TYAs predominantly comprised of Group 4 (40%) and Sonic Hedgehog (SHH)-activated (33%) tumours, with Wingless-type (WNT, 17%) and Group 3 (10%) being less common. TYAs with SHH tumours displayed significantly more gene expression alterations, whereas no gene was detected in the Group 4 tumours. Across MB subgroups, we identified unique and shared sets of TYA-specific differentially methylated probes and DNA-binding motifs. Finally, a 22-gene signature stratified TYA patients into high- and low-risk groups, and the prognostic significance of these risk groups persisted in multivariable regression models ( P = 0.001). This study is an important step toward delineating the molecular landscape of TYAs with MB. The emergence of novel genes and pathways may provide a basis for improved clinical management of TYA with MB. |
